What is the appropriate voriconazole dosing regimen for a 70‑kg adult female with a severe lung infection?

Voriconazole Dosing for Severe Lung Infection in 70kg Female

For a 70kg adult female with severe lung infection (presumed invasive pulmonary aspergillosis), administer voriconazole with a loading dose of 6 mg/kg (420 mg) IV every 12 hours for the first 24 hours, followed by a maintenance dose of 4 mg/kg (280 mg) IV every 12 hours. 1

Initial Intravenous Therapy

The FDA-approved dosing regimen for invasive aspergillosis is:

• Loading dose: 6 mg/kg IV every 12 hours × 2 doses on Day 1
• Maintenance dose: 4 mg/kg IV every 12 hours starting Day 2

For your 70kg patient, this translates to:

• Loading: 420 mg IV every 12 hours × 2 doses
• Maintenance: 280 mg IV every 12 hours

This regimen was validated in the pivotal Study 307/602, which demonstrated 53% satisfactory response versus 32% with amphotericin B, and improved survival (71% vs 58% at Day 84) 1.

Transition to Oral Therapy

After a minimum of 7 days IV therapy and once clinically stable:

• Switch to 200 mg PO every 12 hours 1
• Median duration of IV therapy in clinical trials was 10 days
• Continue oral therapy for median 76 days or until clinical/radiographic resolution

Critical Monitoring Requirements

Therapeutic drug monitoring (TDM) is essential:

• Target trough concentration: 1.0-5.5 mg/L (most commonly cited range) 2
• First trough level: Draw immediately before 5th dose (steady state typically Day 3)
• Timing is critical: Must be true trough (immediately pre-dose), not random level 3
• Recheck after any dose adjustment and weekly initially

Common Pitfalls to Avoid

1. Sampling timing errors: A level drawn 2 hours post-dose can falsely suggest toxicity when concentration is actually therapeutic 3
2. Inflammation effects: Active infection reduces CYP450 activity, increasing voriconazole levels; concentrations may drop significantly after inflammation resolves, requiring dose re-escalation 4
3. Time-varying clearance: Voriconazole exhibits non-linear pharmacokinetics with auto-inhibition; clearance can decrease to 16% of baseline in extensive metabolizers 5

CYP2C19 Genotype Considerations

If genotype available (though not required for initial dosing):

• Extensive metabolizers (EMs): Standard dosing as above
• Intermediate metabolizers (IMs): 17% decreased clearance; may need dose reduction if levels elevated 5
• Poor metabolizers (PMs): 53% decreased clearance; anticipate need for significant dose reduction 5

Without genotype, proceed with standard dosing and adjust based on TDM.

Duration of Therapy

Minimum 7 days IV, then transition to oral for total duration based on:

• Continue until resolution/stabilization of all clinical symptoms
• Continue until resolution/stabilization of radiographic abnormalities
• Typical total duration: 6-12 weeks for pulmonary aspergillosis 6
• Immunocompromised patients may require longer therapy

Alternative Considerations

The 2025 American Thoracic Society guideline suggests either voriconazole monotherapy OR combination with an echinocandin for invasive pulmonary aspergillosis, though evidence was insufficient to favor one approach 7. Combination therapy is more appropriate if:

• Critically ill presentation
• Concern for triazole resistance
• Positive galactomannan assay

For severe disease in this patient, monotherapy with voriconazole at the doses specified above is appropriate initial management 8, 6, with echinocandin addition reserved for inadequate response or critical illness.

Safety Monitoring

Monitor for:

• Visual disturbances (common, usually transient)
• Hepatotoxicity (check LFTs weekly initially)
• QT prolongation (baseline and periodic ECG)
• Photosensitivity reactions
• Drug interactions (particularly with CYP450 substrates)

The key to success is early TDM with proper sampling technique, dose adjustment based on both drug levels and clinical response, and recognition that voriconazole clearance changes over time as inflammation resolves.